VivoSeq
Other

Pulmonary TB

8

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Pulmonary TB is an early-stage landscape with 8 programs across 7 companies. The most active players are Otsuka, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

3 programs

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2O

Orient Pharma Co., Ltd.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Withdrawn1 · 13%
Not yet recruiting1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
Active, not recruiting·GGlobal Alliance for TB Drug Development·Phase 2·NCT06058299·309 enrolled
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Not yet recruiting·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT06205589·1,500 enrolled
Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB
Completed·JJohns Hopkins University·Phase 2·NCT03174184·112 enrolled
A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB
Completed·AAeras·Phase 2·NCT02414828·72 enrolled
Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
Completed·RRadboud University Medical Center·Phase 2·NCT01392911·128 enrolled
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
Completed·—·Phase 2·NCT01785186·365 enrolled
A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
Completed·Otsuka logoOtsuka·Phase 2·NCT05221502·122 enrolled
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
Withdrawn·IInstituto Nacional de Salud Publica, Mexico·N/A·NCT03277742

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)